Despite softness in its nuclear medicine segment, Cardinal Health achieved 10% growth in revenues in the first quarter of fiscal year 2012 (end-September 30).
First-quarter revenue advanced 10% to $26.8 billion, compared with $24.4 billion in the first quarter of fiscal 2011. Adjusted earnings from continuing operations climbed to $256 million, compared with $231 million in the same quarter a year ago.
Revenue in Cardinal's pharmaceutical segment increased 9% to $24.4 billion, compared with $22.3 billion in the same quarter of fiscal 2011.
Jeff Henderson, Cardinal's chief financial officer, said most of the company's businesses performed well in the first quarter, but lackluster results were seen in its cardiac imaging area.
